Journal
NATURE CANCER
Volume 2, Issue 12, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s43018-021-00275-9
Keywords
-
Categories
Funding
- Cancer Research UK [C50947/A18176]
- Francis Crick Institute - Cancer Research UK (CRUK) [FC001988, FC001218, FC001099, FC001002, FC001078, FC001169, FC001030]
- UK Medical Research Council [FC001988, FC001218, FC001099, FC001002, FC001078, FC001169, FC001030, FC10988]
- Wellcome Trust [FC001988, FC001218, FC001099, FC001002, FC001078, FC001169, FC001030, FC10988, FC0010218, 203135, 222754]
- National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden Hospital
- Institute of Cancer Research [A109]
- Royal Marsden NHS Foundation Trust
- Royal Marsden Cancer Charity
- European Union [892360]
- CRUK [FC10988, FC0010218, A29911]
- Francis Crick Institute
- NIHR BRC at the Royal Marsden Hospital
- Rosetrees Trust [A2204, M926]
- Ventana Medical Systems [10467, 10530]
- National Institute of Health [U01 CA247439]
- Melanoma Research Alliance [686061]
- Royal Society Napier Research Professor [RP150154]
- Francis Crick Institute - CRUK [FC001169]
- CRUK (TRACERx, PEACE and CRUK Cancer Immunotherapy Catalyst Network)
- CRUK Lung Cancer Centre of Excellence
- Rosetrees Trust
- Butterfield Trust
- Stoneygate Trust
- Novo Nordisk Foundation [ID16584]
- Royal Society Research Professorship Enhancement Award [RP/EA/180007]
- NIHR BRC at University College London Hospitals
- CRUK-UCL Centre
- Experimental Cancer Medicine Centre
- Breast Cancer Research Foundation, USA
- Stand Up To Cancer (SU2C)-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant [SU2C-AACR-DT23-17]
- European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013) [FP7-THESEUS-617844]
- European Commission ITN [607722]
- ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020 Research and Innovation program [835297]
- Chromavision from the European Union's Horizon 2020 Research and Innovation program [665233]
- UKRI [FC0010218]
- South African Medical Research Council
- Marie Curie Actions (MSCA) [892360] Funding Source: Marie Curie Actions (MSCA)
Ask authors/readers for more resources
Patients with cancer have higher morbidity and mortality when infected with COVID-19. The CAPTURE study found that while most patients had immune responses against the original SARS-CoV-2, neutralizing antibody titers against variants were significantly reduced, with some patients experiencing a decrease in antibody levels. However, neutralizing antibody titers remained stable for some patients.
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4(+) responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer. Turajlic and colleagues assess longitudinal antibody and cellular immune responses against SARS-CoV-2 variants of concern in patients with cancer, following either recovery from SARS-CoV-2 infection or vaccination, in two back-to-back reports from the CAPTURE study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available